Microgentas is a biotechnology startup founded in 2021, focused on becoming a global leader in Extracellular Vesicle (EV) isolation and EV-based diagnostics. The company's core technologies, including ExoCAS™, ExoPAS™, ExoFilter™, ExoTFF™, and miRQuick™, offer faster, cost-effective, scalable, and user-friendly exosome isolation and miRNA extraction kits. Microgentas is collaborating with Korea University Anam Hospital to develop EV research related to exosome-based biomarkers for diagnosing and monitoring breast cancer. Additionally, the startup is partnering with cosmetic companies to explore the use of exosomes as ingredients.
Name: Microgentas
Slogan: Global leader in Extracellular Vesicle Isolation and EV-based Diagnostics
Description: Microgentas focuses on integrated exosome isolation and miRNA extraction. The company provides solutions to sample preparation challenges with its core technologies, offering faster, cost-effective, scalable, user-friendly exosome isolation kits: ExoCAS™, ExoPAS™, ExoFilter™, ExoTFF™, and exosomal microRNA extraction kits, miRQuick™. Microgentas is also developing EV research related to exosome-based biomarkers for diagnosing and monitoring breast cancer, collaborating with Korea University Anam Hospital. Also collaborating with cosmetic companies who are willing to use exosome as their ingredients.
Founded: 2021
Industries: Biotechnology, Health Care
Headquarter: N/A
Last Investment: N/A
Last Investment Investors: N/A
Taxonomy:
Extracellular Vesicle Isolation, EV based Diagnostics, Exosome Isolation, miRNA Extraction, Liquid Biopsy, Cancer Research, Breast Cancer, Biomarker Development, Medical Diagnostics, Collaborative Research, Biomedical Technology, Cosmetic Ingredients, Sample Preparation Solutions
Korea South
